Autolus Therapeutics plc (NASDAQ:AUTL) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB raised its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 30.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,300 shares of the company’s stock after acquiring an additional 17,300 shares during the period. Handelsbanken Fonder AB’s holdings in Autolus Therapeutics were worth $172,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Wellington Management Group LLP lifted its position in Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares during the period. FMR LLC lifted its holdings in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after buying an additional 5,478,706 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Autolus Therapeutics by 145.3% in the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock worth $4,663,000 after buying an additional 761,008 shares during the last quarter. State Street Corp grew its holdings in Autolus Therapeutics by 1.7% during the third quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after acquiring an additional 10,401 shares during the period. Finally, HighVista Strategies LLC raised its position in Autolus Therapeutics by 2.7% during the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock valued at $1,935,000 after acquiring an additional 14,204 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

Shares of AUTL stock opened at $1.75 on Tuesday. Autolus Therapeutics plc has a 1-year low of $1.68 and a 1-year high of $6.63. The company has a market cap of $465.66 million, a price-to-earnings ratio of -1.45 and a beta of 2.02. The stock has a 50 day simple moving average of $2.17 and a 200-day simple moving average of $3.12.

Analyst Ratings Changes

Several research firms have commented on AUTL. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.